Prof. Steve Wedge

• Professor of Stratified Cancer Med Discovery
• Email: steve.wedge@ncl.ac.uk
• Telephone: +44 (0) 191 208 4418

Steve joined the Newcastle Drug Discovery Unit in June 2012. He previously worked at AstraZeneca for 16 years, with a key role in projects that led to the nomination of 12 candidate drugs, six of which were progressed clinically. This included being a lead bioscientist on the programme that resulted in the discovery of vandetanib (CaprelsaÒ), the first targeted therapy to be approved for the treatment of medullary thyroid cancer. He has a track record in critical problem solving with experience across all drug discovery phases; from target selection and validation, through lead identification and optimisation, to supporting translational science and early clinical development. He is currently Vice Chair of CRUK’s Small Molecule Expert Review Panel (SMERP) and a member of their Drug Discovery Committee (DDC) and New Agents Committee (NAC). Steve takes overall responsibility for management of the CRUK Newcastle Drug Discovery Unit and target entry into the portfolio. University profile.